摘要
目的评价地西他滨联合半量CAG治疗老年性及复发难治性急性髓细胞白血病(AML)的临床疗效。方法收集2012年2月至10月在我科接受地西他滨治疗的10例AML患者的临床资料,评价其疗效和不良反应。结果初治老年患者3例,完全缓解2例,总有效率为66.7%;复发难治患者7例,完全缓解3例,部分缓解2例,总有效率为71.4%。血液学不良反应发生率100%,感染发生率70%,轻度肝功能损害发生率30%,无严重出血及恶心、呕吐等。结论地西他滨联合半量CAG可有效治疗老年性及复发难治性AML,但血液学不良反应较重,感染发生率较高,必须给予相应的监测和支持治疗。
Objective To evaluate the clinical efficacy of decitabine combined with half quantity of CAG regiment on elderly and refractory or relapsed acute myeloid leukemia （AML）. Methods We collected clinical data of ten diagnosed cases of acute myeloid leukemia who were admitted to the First Affiliated Hospital of China Medical Uuniversity between Feb. 2012 and Oct. 2012. Results Of three newly di- agnosed elderly patients, two achieved complete remission （CR）, the overall response rate was 66.7%. Of seven refractory or relapsed pa- tients,three cases achieved complete remission （CR） ,two cases achieved partial remission （PR） ,and the overall response rate was 71.4%. Hematologic toxicity was 100% ,tile incidence rate of infection was 70%, and mild liver injury was 30%. No severe bleeding, nausea and vomiting was observed. Conclusion Decitabine combined with half quantity of CAG regiment can effectively treat elderly and/or refractory or relapsed acute myeloid leukemia, but hematologic toxicity and infections is severe, it is necessary to give appropriate monitoring and sup- portive treatment.
出处
《中国医科大学学报》
CAS
CSCD
北大核心
2013年第6期515-517,共3页
Journal of China Medical University
基金
辽宁省医学高峰建设工程(2010010)
沈阳市科学技术计划(F12-277-1-21)
